Literature DB >> 7893377

Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia.

H Ichinose1, T Ohye, K Fujita, F Pantucek, K Lange, P Riederer, T Nagatsu.   

Abstract

Using the reverse transcription-polymerase chain reaction (RT-PCR), we developed a sensitive and quantitative method to detect all four types of human tyrosine hydroxylase (TH) mRNAs in the human brain (substantia nigra). All four types of TH mRNAs were found in the substantia nigra in the control brains examined, and the ratio of type-1, type-2, type-3, and type-4 mRNAs to the total amount of TH was 45, 52, 1.4, and 2.1%, respectively. The average amount of total TH mRNA in the normal brain (substantia nigra) was 5.5 amol of TH mRNA per microgram of total RNA. The ratios of four TH isoforms were not altered significantly in Parkinson's disease or schizophrenia. Further we measured the relative amount of aromatic L-amino acid decarboxylase (AADC) and beta-actin mRNAs in the brain samples. TH and AADC mRNAs were highly correlated in the control cases. We found that parkinsonian brains had very low levels of all four TH isoforms and AADC mRNAs in the substantia nigra compared with control brains, while no significant differences were found between schizophrenic brains and normal ones. Since the decrease in AADC mRNA was comparable to that in TH mRNA, the alteration of TH in Parkinson's disease would not be a primary event, but it would reflect the degeneration of dopaminergic neurons in the substantia nigra. This is the first reported measurement of mRNA contents of TH isoforms and AADC in Parkinson's disease and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7893377     DOI: 10.1007/bf02250926

Source DB:  PubMed          Journal:  J Neural Transm Park Dis Dement Sect        ISSN: 0936-3076


  37 in total

1.  L-Dopa decarboxylase expression profile in human cancer cells.

Authors:  Ioanna Chalatsa; Eleftheria Nikolouzou; Emmanuel G Fragoulis; Dido Vassilacopoulou
Journal:  Mol Biol Rep       Date:  2010-06-11       Impact factor: 2.316

Review 2.  Parkinson's disease: gene therapies.

Authors:  Philippe G Coune; Bernard L Schneider; Patrick Aebischer
Journal:  Cold Spring Harb Perspect Med       Date:  2012-04       Impact factor: 6.915

Review 3.  A possible pathophysiological role of tyrosine hydroxylase in Parkinson's disease suggested by postmortem brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. Peter Riederer.

Authors:  Akira Nakashima; Akira Ota; Yoko S Kaneko; Keiji Mori; Hiroshi Nagasaki; Toshiharu Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2012-05-27       Impact factor: 3.575

4.  Purification of an endogenous inhibitor of L-Dopa decarboxylase activity from human serum.

Authors:  Alice-Georgia Vassiliou; Dido Vassilacopoulou; Emmanuel G Fragoulis
Journal:  Neurochem Res       Date:  2005-05       Impact factor: 3.996

5.  PKCδ inhibition enhances tyrosine hydroxylase phosphorylation in mice after methamphetamine treatment.

Authors:  Eun-Joo Shin; Chu Xuan Duong; Xuan-Khanh Thi Nguyen; Guoying Bing; Jae-Hyung Bach; Dae Hun Park; Keiichi Nakayama; Syed F Ali; Anumantha G Kanthasamy; Jean L Cadet; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Neurochem Int       Date:  2011-06-13       Impact factor: 3.921

6.  Release of membrane-associated L-dopa decarboxylase from human cells.

Authors:  Ioanna Chalatsa; Emmanuel G Fragoulis; Dido Vassilacopoulou
Journal:  Neurochem Res       Date:  2011-04-11       Impact factor: 3.996

Review 7.  GTP cyclohydrolase I gene, tetrahydrobiopterin, and tyrosine hydroxylase gene: their relations to dystonia and parkinsonism.

Authors:  T Nagatsu; H Ichinose
Journal:  Neurochem Res       Date:  1996-02       Impact factor: 3.996

8.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.

Authors:  Gabriele Mittermeyer; Chadwick W Christine; Kathryn H Rosenbluth; Suzanne L Baker; Philip Starr; Paul Larson; Paul L Kaplan; John Forsayeth; Michael J Aminoff; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-04-10       Impact factor: 5.695

9.  Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia.

Authors:  Matthew W Rice; Rosalinda C Roberts; Miguel Melendez-Ferro; Emma Perez-Costas
Journal:  Brain Struct Funct       Date:  2014-10-01       Impact factor: 3.270

Review 10.  Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.

Authors:  Toshiharu Nagatsu; Ikuko Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.